comprehensive -WSS

comprehensive

author：leisure time 2025-08-25 07:28:25 - browse：5625

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Scientists inch closer to single

hotspot

WSS

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Amazon on where the company's health care bets are headed next

Stem cell treatment guidelines are released by FDA

The (many) problems with a new study criticizing cancer screening

Wildfire pollution widens asthma inequities on Long Island

No plane should take off without an EpiPen onboard

knowledge

comprehensive

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Mitch McConnell episode has important public health takeaway

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Dobbs anniversary: the lost opportunity of abortion as health care

Mitch McConnell episode has important public health takeaway

BioMarin wins approval for gene therapy to treat hemophilia A

The high personal cost of affirmative action for Black doctors

Heart attack and stroke risk calculators need revising

How to protect patients from sexual assault

entertainment

New safety details link Apellis eye drug to rare cases of blindness

Amazon on where the company's health care bets are headed next

Pence says 'crackpot lawyers' told Trump what he wanted to hear

What drug price negotiations mean for Medicare Part D

The (many) problems with a new study criticizing cancer screening

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

focus

hotspot

explore

focus